Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia

European Respiratory Journal

Volumn 38, Issue 1, 2011, Pages 218-220

  Dumitrescu, D ^a   Seck, C ^a   Ten Freyhaus, H ^a   Gerhardt, F ^a   Erdmann, E ^a   Rosenkranz, S ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; ILOPROST; IMATINIB; LIVER ENZYME; NILOTINIB; PEGINTERFERON ALPHA; SILDENAFIL;

ADULT; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DIZZINESS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; HEART RIGHT BUNDLE BRANCH BLOCK; HEPATOMEGALY; HUMAN; LETTER; MALE; PERIPHERAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; RASH; RECURRENT DISEASE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HEART MURMUR; TACHYCARDIA; THORACOCENTESIS; TREATMENT DURATION; VENOUS CONGESTION;

ANTINEOPLASTIC AGENTS; BLOOD PRESSURE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PULMONARY MEDICINE; PYRIMIDINES; THIAZOLES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 79960181854     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00154210     Document Type: Letter

References (17)

1. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 2009; 34: 1219-1263.
2. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821. (Pubitemid 41434408)
3. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353: 1412-1413. (Pubitemid 41362714)
4. Patterson KC, Weissmann A, Ahmadi T, et al. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006; 145: 152-153. (Pubitemid 46780594)
5. Souza R, Sitbon O, Parent G, et al. Long term imatinib treatment in pulmonary arterial hypertension. Chest 2006; 61: 736. (Pubitemid 44211786)
6. ten Freyhaus H, Dumitrescu D, Bovenschulte H, et al. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin Res Cardiol 2009; 98: 265-267.
7. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182: 1171-1177.
8. Perros F, Montani D, Dorfmü ller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 81-88. (Pubitemid 351919196)
9. Quinta's-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007; 25: 3908-3914.
10. Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009; 33: 861-864.
11. Mattei D, Feola M, Orzan F, et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009; 43: 967-968.
12. Kovacs G, Berghold A, Scheidl S, et al. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009; 34: 888-894.
13. Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110: 4055-4063. (Pubitemid 350248462)
14. Chen Z, Lee F, Bhalla K, et al. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by bms-354825 (dasatinib). Mol Pharmacol 2006; 69: 1527-1533.
15. Rosenkranz S, Ikuno Y, Leong FL, et al. Src family kinases negatively regulate platelet-derived growth factor a receptor-dependent signaling and disease progression. J Biol Chem 2000; 275: 9620-9627. (Pubitemid 30185194)
16. Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908-916. (Pubitemid 44175142)
17. Bergeron A, Rea D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007; 176: 814-818. (Pubitemid 47598483)